Mass vaccination campaigns reduce the substantial burden of yellow fever in Africa

May 6, 2014

Yellow fever, an acute viral disease, is estimated to have been responsible for 78,000 deaths in Africa in 2013 according to new research published in PLOS Medicine this week. The research by Neil Ferguson from Imperial College London, UK and colleagues from Imperial College, WHO and other institutions also estimates that recent mass vaccination campaigns against yellow fever have led to a 27% decrease in the burden of yellow fever across Africa in 2013.

Yellow fever is a serious viral disease that affects people living in and visiting tropical regions of Africa and Central and South America. In rural areas next to forests, the virus typically causes sporadic cases or even small-scale epidemics (outbreaks) but, if it is introduced into urban areas, it can cause large explosive epidemics that are hard to control. Although many people who contract yellow fever do not develop any symptoms, some have mild flu-like symptoms, and others develop a high fever with jaundice or hemorrhaging from the mouth, nose, eyes, or stomach. About 50% of patients who develop these severe symptoms die. Fortunately, an effective vaccine against the disease exists.

The authors of the study used sophisticated statistical methods to estimate the burden of yellow fever in Africa based on outbreak data, serological surveys and environmental data but note that there is substantial uncertainty in their estimates because of the difficulty of diagnosing yellow fever and a lack of available data. Therefore the estimates for the number of severe cases of yellow fever in Africa in 2013 range from 51,000 to 380,000, and from 19,000 to 180,000 for deaths due to the disease

Nevertheless, the study provides the most reliable contemporary estimates for the burden of yellow fever and the impact of vaccination campaigns in Africa. The researchers estimate that vaccination has reduced yellow fever cases and deaths by 27% across Africa, with much higher reductions in some countries targeted by vaccination campaigns. The authors note that their study has already been influential, "[p]artly as a result of [our estimates], in late 2013 the GAVI [Global Alliance for Vaccines and Immunization] Board decided to make available support for additional yellow fever vaccination campaigns, targeting 144 million people across the endemic region in Africa"

The authors also note, "[t]he impact of both past and future mass vaccination campaigns will prevent a substantial proportion of disease burden for years to come... the achievements of the current campaigns could be sustained if a high level of immunization is achieved through a strong EPI [infant immunization] program and preventive vaccination of populations that remain at risk, such as migrants or populations from as yet unvaccinated districts."

Explore further: WHO says single yellow fever shot is enough

More information: Garske T, Van Kerkhove MD, Yactayo S, Ronveaux O, Lewis RF, et al. (2014) Yellow Fever in Africa: Estimating the Burden of Disease and Impact of Mass Vaccination from Outbreak and Serological Data. PLoS Med 11(5): e1001638. DOI: 10.1371/journal.pmed.1001638

Related Stories

WHO says single yellow fever shot is enough

May 17, 2013
(AP)—The World Health Organization says a yellow fever booster vaccination given 10 years after the initial shot isn't necessary.

WHO: 107 dead from yellow fever in Darfur, Sudan

November 13, 2012
(AP)—A yellow fever outbreak in Sudan's Darfur region has killed 107 people in the last six weeks, the World Health Organization reported Tuesday, warning that the disease could spread all over the country.

Darfur yellow fever outbreak worst in decades

December 6, 2012
An outbreak of mosquito-borne yellow fever which has killed at least 165 people in Sudan's Darfur region is Africa's worst in decades, the World Health Organisation said on Thursday.

Darfur's yellow fever shows 'no sign of stopping'

December 6, 2012
A rare outbreak of mosquito-borne yellow fever which has killed 165 people in Sudan's Darfur region in the past three months continues to spread, the UN warned on Thursday.

Darfur yellow fever deaths double to 67: UN agency

November 6, 2012
The number of people believed to have died from mosquito-borne yellow fever in Sudan's conflict-plagued Darfur region has doubled to 67, health officials said on Tuesday.

Yellow fever shots begin in Sudan's Darfur

November 22, 2012
Health workers in Sudan's Darfur region have begun vaccinating more than two million people against a rare yellow fever outbreak suspected of killing 124 since late September, medics said on Thursday.

Recommended for you

Pair of discoveries illuminate new paths to flu and anthrax treatments

October 17, 2017
Two recent studies led by biologists at the University of California San Diego have set the research groundwork for new avenues to treat influenza and anthrax poisoning.

Portable 3-D scanner assesses patients with elephantiasis

October 17, 2017
An estimated 120 million people worldwide are infected with lymphatic filariasis, a parasitic, mosquito-borne disease that can cause major swelling and deformity of the legs, a condition known as elephantiasis. Health-care ...

New tools to combat kidney fibrosis

October 16, 2017
Interstitial fibrosis – excessive tissue scarring – contributes to chronic kidney disease, which is increasing in prevalence in the United States.

How hepatitis C hides in the body

October 13, 2017
The Hepatitis C (HCV) virus is a sly enemy to have in one's body. Not only does it manage to make itself invisible to the immune system by breaking down communication between the immune cells, it also builds secret virus ...

Largest study yet of malaria in Africa shows historical rates of infection

October 12, 2017
(Medical Xpress)—A team of researchers with members from the Kenya Medical Research Institute, the University of Oxford and the University of KwaZulu-Natal has conducted the largest-ever study of the history of malaria ...

Promising new target for treatment of psoriasis is safe, study shows

October 11, 2017
A protein known to play a significant role in the development of psoriasis can be prevented from functioning without posing a risk to patients, scientists at King's College London have found.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.